Clarithromycin as inherent component of anti-helicobacter therapy


如何引用文章

全文:

详细

The article is devoted to the review of current treatment regimens of Helicobacter pylori infection and place them clarithromycin. Current recommendations of international consensus Maastricht II-III are presented. We discussed the possible ways to solve the main problems associated with increasing antibiotic resistance of H. pylori. The basic reasons for its development are stated. Particular attention is paid to the prospects of new regimens, in particular the eradication treatment regimen with clarithromycin administration, and to the quality of antibacterial drugs.

参考

  1. Белоусов Ю.Б. Дженерики - мифы и реалии. Remedium. 2003. № 7-8. С. 4-9.
  2. Дехнич Н.Н., Козлов С.Н. Кларитромицин (Клацид) - роль в эрадикации Helicobacter pylori-инфекции // Фарматека. 2007. № 13. С. 1-6.
  3. Захарова Н.В. Комбинированная схема эрадикации Helicobacter pylori // Россицский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006. № 3. С. 45-51.
  4. Калинин А.В. Резистентность Helicobacter pylori к антибиотикам и пути ее преодоления. Место Де-Нола в современных схемах эрадикационной терапии // Терапевтический архив. 2001. № 8. С. 73-75.
  5. Кудрявцева Л.В. Биологические свойства Helicobacter pylori // Альманах клинической медицины. 2006. Т. XIV. С. 39-46.
  6. Маев И.В., Самсонов А.А., Голубев Н.Н. и др. Опыт применения кларитромицина в семи- и четырнадцатидневных схемах эрадикационной терапии при язвенной болезни двенадцатиперстной кишки // Лечащий врач. 2007. № 6. С. 88-89.
  7. Ивашкин В.Т., Лапина Т.Л. и др. Рациональная фармакотерапия заболеваний органов пищеварения: Рук. для практикующих врачей / Под общ. ред. В.Т. Ивашкина. М.: Литтерра, 2003. 1046 с.
  8. Рачина С.А., Страчунский Л.С., Козлов Р.С. Кларитромицин: есть ли потенциал для клинического применения в XXI веке? // Клин. микробиол. антимикроб. химиотер. 2005. № 4. С. 369-392.
  9. Ушакова Е.А. Проблемы фальсификации лекарственных средств: фокус на антимикробные препараты // Клиническая микробиология и антимикробная химиотерапия. 2005. № 2. С. 167-173.
  10. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin-containing "rescue therapy" for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:481-88.
  11. Bruce MG, Bruden PL, McMahon BJ, et al. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter 2006;11(6):581-88.
  12. Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2002;14:603-09.
  13. Chey WD, Wong BCY. American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection. Am J Gastroenterol 2007;102:1808-25.
  14. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007;59(4):783-85.
  15. De Francesco V, Della Valle N, Stoppino V, et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004;19:993-98.
  16. De Francesco V, Zullo A, Hassan C, et al.The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study. Dig Liver Dis 2004;36:322-26.
  17. Delgado J, Bujanda L, Gisbert P, et al. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice. Gastroenterol 2007;132:A-112.
  18. Dzierzanowska-Fangrat K, Rozynek, Celinska-Cedro D, et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Antimicrob Agents 2005;26(3):230A.
  19. Fischbach LА, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
  20. Focareta R, Forte G, Forte F, et al. Could the 10-days sequential therapy be considered a first choice treatment for the eradication of Helicobacter pylori infection? Dig Liver Dis 2003;35(Suppl. 4):S33.
  21. Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterol 2005;129:1414-19.
  22. Gene E, Calvert X, Azagra R, et. al. Triple vs quadruple therapy for treating Helicobacter pylori infection: An updated meta-analysis. Aliment Pharmacol Ther 2003;18:543-44.
  23. Giannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose Levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006;23:281-87.
  24. Gisbert JP, Gisbert JL, Marcos S, et al. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006;24:1469-74.
  25. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
  26. Gustavson LE, Kaiser JF, Edmonds AL, et al. Edmonds effect of omeprazol on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995;39:2078-83.
  27. Hassan C, De Francesco V, Zullo A, et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 2003;18:641-46.
  28. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
  29. Isakov V, Domareva I, Koudryavtseva L, et al. Furazolidone-based triple 'rescue therapy' vs. quadruple rescue therapy for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002;16:793-98.
  30. Jafri NS, Hornung CA, Howden CW. Meta-analysis: Sequential Therapy Appears Superior to Standard Therapy for Helicobacter pylori Infection in Patients Naive to Treatment. Ann Intern Med 2008;148:923-31.
  31. Laine L. It is time for quadruple therapy to be first line. Can J Gastroenterol 2003;17(Suppl. B):33B-5B.
  32. Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-67.
  33. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007;56:772-81.
  34. Malfertheiner Р, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.
  35. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
  36. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006;24:395-403.
  37. Nightingale CH. A survey of the Quality of Generic Clarithromycin Product from 18 Countries. Clin Drug Invest 2005;25:135-52.
  38. O'Morain C, Borody T, Farley A, et al. International multicentre study efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003;17:415-20.
  39. Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clanthromycin in Turkey. J Clin Gastroenterol 2007;41:747-50.
  40. Rinaldi V, Zullo A, Pugliano F, et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997;11:929-33.
  41. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
  42. Saito M, YasuiFurukori N, Uno T, et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol 2005;59:302-09.
  43. Schabereiter-Gurtner C, Hirschl AM, Dragosics B, et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 2004;42:4512-18.
  44. Sullivan B, Coyle W, Nemec R, et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002;97:2536-39.
  45. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
  46. Wong WM, Wong BC, Lu H, et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002;16:793-98.
  47. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##